Independent register of U.S. FDA drug recalls · updated Oct 14, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Class II · Moderate risk

PredniSONE Tablets USP

Failed Tablet/Capsule Specifications: Discovery of an underweight tablet.

Terminated Failed specification West-Ward Pharmaceutical NDC 0054-4741-25 D-0008-2017
Class III · Low risk

Paricalcitol Capsules

Failed Impurities/Degradation Specifications: This repackaged product was recalled by its manufacturer due to failed results for impurities.

Terminated Impurity / degradation Amerisource Health Services NDC 60687-106-25 D-0009-2017
Class III · Low risk

Clonazepam Tablets

Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 16 month timepoint.

Terminated Impurity / degradation Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-882-20 D-0136-2017
Class III · Low risk

Clonazepam Tablets

Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 15 month timepoint.

Terminated Impurity / degradation Mylan Institutional, Inc. (d.b.a. UDL Laboratories) NDC 51079-881-20 D-0135-2017
Class III · Low risk

PARICALCITOL Capsules

Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7658-56 D-0111-2017
Class III · Low risk

PARICALCITOL Capsules

Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7657-56 D-0110-2017
Class III · Low risk

PARICALCITOL Capsules

Failed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7656-56 D-0109-2017

Recalls by year